Jyseleca

Jyseleca is a medicine for treating adults with: - moderate to severe rheumatoid arthritis, a disease in which the immune system (the body’s natural defences) attacks healthy tissue causing inflammation and pain in joints. Jyseleca is used alone or with another medicine, methotrexate, after treatment with one or more disease-modifying anti-rheumatic drugs (DMARDs) has not worked well enough or ha caused unacceptable side effects. DMARDs are medicines, such as methotrexate, that slow down the worsening of the disease. - moderately to severely active ulcerative colitis, a condition in which the immune system attacks healthy tissue in parts of the intestine, causing periodical inflammation leading to sores and bleeding. In this case, Jyseleca is given to patients for whom conventional or biological therapies have not worked well enough, have stopped working or are not tolerated. Jyseleca contains the active substance filgotinib. Jyseleca is also used to treat adults with moderately to severely active ulcerative colitis, a condition in which the immune system attacks healthy tissue in parts of the intestine, causing periodical inflammation leading to sores and bleeding. In this case, Jyseleca is given to patients for whom conventional or biological therapies have not worked well enough, have stopped working or are not tolerated. Jyseleca contains the active substance filgotinib.